Table 1.
Patient characteristics.
| Number | 32 (6/14/12)* |
| Age, median (range) | 61 (36–76) |
| Sex | |
| Male | 28 (4/13/11)* |
| Female | 4 (2/1/1)* |
| ECOG | |
| 0 | 8 |
| 1 | 24 |
| Liver cirrhosis | |
| Yes | 22 (3/11/8)* |
| No | 9 (3/2/4)* |
| Cause of liver disease | |
| HBV | 5 (2/1/2)* |
| HCV | 19 (3/11/5)* |
| Baseline Child-Pugh score | |
| 5 | 14 (2/6/6)* |
| 6 | 5 (1/3/1)* |
| 7 | 3 (-/2/1)* |
| Number of lesions | |
| 1 | 5 |
| 2 | 3 |
| 3–5 | 12 |
| >5 | 8 |
| BCLC stage | |
| B | 7 |
| C | 21 |
| Extrahepatic disease | |
| Yes | 14 (2/10/2)* |
| No | 17 (4/4/9)* |
| Prior sorafenib | |
| Yes/no | 21/7 |
| DC due to PD/intolerant | 18/3 |
| Other systemic therapies | 9 |
| Other previous interventions | |
| TACE | 11 |
| Surgery | 5 |
| Ablation | 5 |
| Reason for discontinuation | |
| PD | (5/12/3)* |
| Toxicity | (1/2/1)* |
BCLC, Barcelona Clinic Liver Cancer; DC, discontinued; ECOG, Eastern Cooperative Oncology Group; PD, progressive disease; TACE, transcatheter arterial chemoembolization.
*
Dose level 1/Dose level 2 ablation/Dose level 2 TACE.